|
Hepatitis B
|
0.310 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis B
|
0.310 |
Biomarker
|
disease |
BEFREE |
Here, we report that miR-148a is repressed by hepatitis B virus (HBV) X protein (HBx) to promote cancer growth and metastasis in a mouse model of hepatocellular carcinoma (HCC).
|
23321675 |
2013 |
|
Kidney Failure, Acute
|
0.300 |
Biomarker
|
disease |
CTD_human |
A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats.
|
30682439 |
2019 |
|
Acute Kidney Insufficiency
|
0.300 |
Biomarker
|
disease |
CTD_human |
A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats.
|
30682439 |
2019 |
|
Acute kidney injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats.
|
30682439 |
2019 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Pancreatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.
|
27840954 |
2016 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.
|
25359176 |
2015 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to determine the levels of miR-148a and integrin subunit alpha 9 (ITGA9) in glioblastoma tissues and cells and their involvement in cancer cell proliferation and migration.
|
31489579 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Rise in miR-21-5p expression and decreased blood level of miR-148a-3p was associated with higher stage of NSCLC.
|
31236600 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Survival analysis revealed that let-7c-5p, miR-148a-3p, and miR-148a-5p levels correlated with NSCLC prognosis.
|
31176168 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of that, miR-148a-3p and SOS2 may be an efficient target in developing more useful therapies against NSCLC.
|
30536836 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the clinical samples, miR-184a was found to be down-regulated in CRC tissues, down-regulation of miR-148a predicted poor prognosis in CRC patients.
|
30551544 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The dual luciferase reporter assay was employed to confirm miR-148a regulated the expression of ErbB3 in colorectal cancer.
|
31402949 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings support the important role of miR-21 in stages I-II of CRC, and the KRAS G12D mutant, and differential miR-148a expression, in advanced stages of CRC.
|
30997628 |
2019 |